Superstring Capital: Funding, Team & Investors | Startup Intros

Loading organizations...

Superstring Capital: Funding, Team & Investors | Startup Intros

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
May 1, 2024	Zenas BioPharma	$200.0M Series C	SR One Capital Management, Tim Xiao, NEA, Norwest Venture Partners	Vivo Capital, ArrowMark Partners, Enavate Sciences, Fairmount, Hermes GPE, Longitude Capital, Pivotal bioVenture Partners, Quan Capital, Rock Springs Capital, Wellington Management
Apr 12, 2024	Century Therapeutics	$60.0M Other Equity	Adage Capital Management, Bain Capital Life Sciences, Octagon Capital, Superstring Capital	Boxer Capital, Casdin Capital, Dafna Capital, Venrock
Jan 1, 2024	Orange Dental	$130.0M Series B	Oceanpine Capital, OrbiMed	3W Capital, Adjuvant Capital, AIHC Capital, Eight Roads Ventures, F-Prime Capital, Haitong International, Hillhouse Capital Group, MSA Capital
Nov 1, 2022	Zenas BioPharma	$120.0M Series B	James Boylan	venBio, Vivo Capital, Agent Capital, Fairmount, Patrick Enright, Perceptive Advisors, Pivotal bioVenture Partners, Quant Venture Fund, Rock Springs Capital, Tellus BioVentures, Wellington Management, Xencor
Aug 1, 2022	Sironax	$200.0M Series B	Gaorong Capital, Xiao (Albert) Huang	F-Prime Capital Partners, Abu Dhabi Investment Authority, ARCH Venture Partners, CBC Group, Eight Roads Ventures, F-Prime Capital, Future Innovation Fund, Invus, K2 Venture Partners, LongRiver Investments, LSV Capital, MSA Capital, Temasek
Oct 1, 2021	ReCode Therapeutics	$80.0M Series B	Oleg Nodelman	Bioluminescence Ventures, InterWest, MPM Capital, OrbiMed, Pfizer Venture Investments, Polaris Partners, Vida Ventures, Sam Altman, Colt Ventures, Hunt Technology Ventures, NS Investment, Osage University Partners, Sanofi Ventures, Tekla Capital Management
Jul 10, 2021	dMed	$50.0M Series C	Springhill Fund	Fidelity Management & Research Company, Hongshan Capital Group (Sequoia Capital China), Kaiser Permanente, Rock Springs Capital
Jul 7, 2021	Clinipace	$50.0M Series C	Springhill Fund	Rock Springs Capital
Mar 30, 2021	AffaMed Therapeutics	$170.0M Series B	Bin Li	Wei Fu, Fountainhead Partners, Orion Science Capital, Partners Investment
Feb 1, 2021	LakeShore Biopharma	$130.0M Series B	OrbiMed, Dave Chenn	3W Capital, Adjuvant Capital, AIHC Capital, Eight Roads Ventures, Epiphron Capital, F-Prime Capital, Haitong International, Hillhouse Capital, MSA Capital